145 related articles for article (PubMed ID: 21925887)
1. Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.
Vardanyan R; Kumirov VK; Nichol GS; Davis P; Liktor-Busa E; Rankin D; Varga E; Vanderah T; Porreca F; Lai J; Hruby VJ
Bioorg Med Chem; 2011 Oct; 19(20):6135-42. PubMed ID: 21925887
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional μ/δ-Opioid Agonist-Neurokinin Antagonist Peptidomimetics.
Gadais C; Piekielna-Ciesielska J; De Neve J; Martin C; Janecka A; Ballet S
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500841
[TBL] [Abstract][Full Text] [Related]
3. Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse.
Neumeyer JL; Mello NK; Negus SS; Bidlack JM
Pharm Acta Helv; 2000 Mar; 74(2-3):337-44. PubMed ID: 10812979
[TBL] [Abstract][Full Text] [Related]
4. Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.
Yamamoto T; Nair P; Jacobsen NE; Kulkarni V; Davis P; Ma SW; Navratilova E; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ
J Med Chem; 2010 Aug; 53(15):5491-501. PubMed ID: 20617791
[TBL] [Abstract][Full Text] [Related]
5. Analgesic Properties of Opioid/NK1 Multitarget Ligands with Distinct in Vitro Profiles in Naive and Chronic Constriction Injury Mice.
Starnowska J; Costante R; Guillemyn K; Popiolek-Barczyk K; Chung NN; Lemieux C; Keresztes A; Van Duppen J; Mollica A; Streicher J; Vanden Broeck J; Schiller PW; Tourwé D; Mika J; Ballet S; Przewlocka B
ACS Chem Neurosci; 2017 Oct; 8(10):2315-2324. PubMed ID: 28699350
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors.
Wtorek K; Adamska-Bartłomiejczyk A; Piekielna-Ciesielska J; Ferrari F; Ruzza C; Kluczyk A; Piasecka-Zelga J; Calo' G; Janecka A
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817441
[TBL] [Abstract][Full Text] [Related]
7. Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.
Ballet S; Feytens D; Buysse K; Chung NN; Lemieux C; Tumati S; Keresztes A; Van Duppen J; Lai J; Varga E; Porreca F; Schiller PW; Vanden Broeck J; Tourwé D
J Med Chem; 2011 Apr; 54(7):2467-76. PubMed ID: 21413804
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.
Yamamoto T; Nair P; Largent-Milnes TM; Jacobsen NE; Davis P; Ma SW; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ
J Med Chem; 2011 Apr; 54(7):2029-38. PubMed ID: 21366266
[TBL] [Abstract][Full Text] [Related]
9. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
MacLeod AM; Cascieri MA; Merchant KJ; Sadowski S; Hardwicke S; Lewis RT; MacIntyre DE; Metzger JM; Fong TM; Shepheard S
J Med Chem; 1995 Mar; 38(6):934-41. PubMed ID: 7535362
[TBL] [Abstract][Full Text] [Related]
12. Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor.
MacLeod AM; Merchant KJ; Brookfield F; Kelleher F; Stevenson G; Owens AP; Swain CJ; Casiceri MA; Sadowski S; Ber E
J Med Chem; 1994 Apr; 37(9):1269-74. PubMed ID: 7513763
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyran core: Switch from antagonist to agonist effect by chemical modification.
Recio R; Vengut-Climent E; Mouillac B; Orcel H; López-Lázaro M; Calderón-Montaño JM; Álvarez E; Khiar N; Fernández I
Eur J Med Chem; 2017 Sep; 138():644-660. PubMed ID: 28710964
[TBL] [Abstract][Full Text] [Related]
14. In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera.
Guillemyn K; Kleczkowska P; Novoa A; Vandormael B; Van den Eynde I; Kosson P; Asim MF; Schiller PW; Spetea M; Lipkowski AW; Tourwé D; Ballet S
Mol Brain; 2012 Jan; 5():4. PubMed ID: 22289619
[TBL] [Abstract][Full Text] [Related]
15. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
16. Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.
Le Naour M; Akgün E; Yekkirala A; Lunzer MM; Powers MD; Kalyuzhny AE; Portoghese PS
J Med Chem; 2013 Jul; 56(13):5505-13. PubMed ID: 23734559
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain.
Vardanyan R; Vijay G; Nichol GS; Liu L; Kumarasinghe I; Davis P; Vanderah T; Porreca F; Lai J; Hruby VJ
Bioorg Med Chem; 2009 Jul; 17(14):5044-53. PubMed ID: 19540763
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.
Cascieri MA; Ber E; Fong TM; Hale JJ; Tang F; Shiao LL; Mills SG; MacCoss M; Sadowski S; Tota MR; Strader CD
Eur J Pharmacol; 1997 May; 325(2-3):253-61. PubMed ID: 9163573
[TBL] [Abstract][Full Text] [Related]
20. Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.
Nair P; Yamamoto T; Largent-Milnes TM; Cowell S; Kulkarni V; Moye S; Navratilova E; Davis P; Ma SW; Vanderah TW; Lai J; Porreca F; Hruby VJ
Bioorg Med Chem Lett; 2013 Sep; 23(17):4975-8. PubMed ID: 23899615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
